Eli Lilly CEO says Medicare price negotiations could harm drug developmentThe CEO said the "biggest problem" with the Inflation Reduction Act provision stems from a difference in timeline for negotiating prices on two types of drugs.[Collection]

The CEO said the "biggest problem" with the Inflation Reduction Act provision stems from a difference in timeline for negotiating prices on two types of drugs.https://www.cnbc.com/2023/06/13/eli-lilly-medicare-price-negotiations-could-harm-drug-development-.html